RT @doctorRBC: Deucravacitinib: TYK2 inhibitor in pts with active SLE Phase 2, randomized, double blind, placebo-control
Tweet Content
Deucravacitinib: TYK2 inhibitor in pts with active SLE
Phase 2, randomized, double blind, placebo-controlled study
Met primary endpoint SRI response across all doses
No death, MACE, VTE, systemic infections
@RheumNow #EULAR2022 ABST#LB0004 https://t.co/yAM8qUZgee
Show on Archive Page
On
Display in Search Results
On
PDQ
Off